empagliflozin
Selected indexed studies
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. (N Engl J Med, 2016) [PMID:27299675]
- Empagliflozin attenuates cardiac microvascular ischemia/reperfusion through activating the AMPKα1/ULK1/FUNDC1/mitophagy pathway. (Redox Biol, 2022) [PMID:35325804]
- Safety of Empagliflozin: An Individual Participant-Level Data Meta-Analysis from Four Large Trials. (Adv Ther, 2024) [PMID:38771475]
_Worker-drafted node — pending editorial review._
Connections
empagliflozin is a side effect of
empagliflozin treats
Sources
- Empagliflozin and liraglutide ameliorate HFpEF in mice via augmenting the Erbb4 signaling pathway. (2024) pubmed
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. (2016) pubmed
- Empagliflozin attenuates cardiac microvascular ischemia/reperfusion through activating the AMPKα1/ULK1/FUNDC1/mitophagy pathway. (2022) pubmed
- Safety of Empagliflozin: An Individual Participant-Level Data Meta-Analysis from Four Large Trials. (2024) pubmed
- Empagliflozin attenuates cardiac microvascular ischemia/reperfusion injury through improving mitochondrial homeostasis. (2022) pubmed
- Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. (2015) pubmed
- Empagliflozin in the treatment of heart failure. (2024) pubmed
- Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials. (2018) pubmed
- Empagliflozin protects mice against diet-induced obesity, insulin resistance and hepatic steatosis. (2023) pubmed
- Initial Combination of Empagliflozin and Metformin in Patients With Type 2 Diabetes. (2016) pubmed